FDA Standardizes Bioequivalence Administration Protocols for Generic Chewable Tablets

A systematic regulatory review published in AAPS Open details the standardization of bioequivalence administration methods across United States Food and Drug Administration product-specific guidances for chewable tablets and solid oral dosage forms bearing chewing instructions. Conducted to align regulatory guidance with the FDA bioequivalence guidance for abbreviated new drug applications and the International Council for Harmonisation M13A guidance on immediate-release solid oral dosage forms, the assessment identified eight product-specific guidances requiring revision out of thirty-five relevant immediate-release guidance documents. By systematically evaluating reference listed drug labeling and established biopharmaceutic principles, the regulatory initiative establishes harmonized testing conditions designed to ensure that generic applicants evaluate proposed formulations under the most discriminating test conditions available.

Chewable tablets represent a patient-centric dosage form formulated to be chewed and subsequently swallowed with ease, offering distinct clinical advantages for pediatric and geriatric populations as well as individuals experiencing difficulty swallowing conventional solid oral dosage forms. These formulations frequently incorporate taste-masking technologies, including complexation agents, sweeteners, and flavoring agents, to counteract the bitter taste of active pharmaceutical ingredients and enhance overall patient acceptability and therapeutic adherence. Historically traced to early twentieth-century developments such as chewable aspirin designed for pediatric use, contemporary chewable tablets provide convenient administration options, enhanced palatability, and the potential for a more rapid onset of therapeutic action facilitated by initial mastication within the oral cavity.

To secure marketing approval for generic medications within the United States, prospective applicants must submit an abbreviated new drug application demonstrating that a proposed generic drug product is therapeutically equivalent to its reference listed drug counterpart. Therapeutic equivalence requires establishing both pharmaceutical equivalence and bioequivalence in accordance with Title 21 of the Code of Federal Regulations Part 320. The recent release of the FDA bioequivalence study guidance for abbreviated new drug applications alongside the harmonized ICH M13A guidance provided the foundational regulatory framework necessitating a systematic reassessment of existing product-specific guidance documents.

A critical initial step in standardizing regulatory guidance involved defining explicit dosage form boundaries to distinguish conventional chewable tablets from other solid oral dosage forms that provide chewing instructions. In accordance with the FDA quality attributes guidance for chewable tablets and United States Pharmacopeia General Chapter 1121 Nomenclature Guidelines, true chewable tablets are strictly defined as formulations that must be chewed or crushed prior to swallowing, with no intended alternative mode of administration. Conversely, products whose labeling permits multiple administration methods, such as swallowing whole, chewing completely, or crushing to suspend in liquid, are classified under distinct regulatory nomenclature such as standard tablets or tablets for oral suspension. Commercial examples include ethinyl estradiol and levonorgestrel tablets, which permit either whole swallowing or chewing, and lamotrigine tablets for oral suspension, which allow dispersion, chewing, or whole swallowing.

For immediate-release solid oral dosage forms where labeling presents an option to either chew the tablet or swallow it whole, current FDA bioequivalence guidance recommends that subjects swallow the tablet whole with 240 milliliters of water during bioequivalence trials. Biopharmaceutic rationale dictates that swallowing a tablet whole represents the most discriminating and sensitive test condition for detecting meaningful formulation disparities between a generic product and the reference listed drug. When a tablet is ingested whole, it must first disintegrate in the gastrointestinal tract before active particles dissolve into solution and undergo systemic absorption. Conversely, mastication mechanically breaks down the tablet matrix within the oral cavity into small particles, potentially accelerating dissolution, initiating oral cavity absorption, and masking underlying formulation differences that would otherwise differentiate generic and reference products.

The study authors emphasize that demonstrating bioequivalence by swallowing a whole tablet does not replace the evaluation of physical chewability and palatability attributes required for generic approval. Because suitability for chewing cannot be established through a bioequivalence trial conducted with whole-tablet swallowing, chewability is independently scrutinized during the abbreviated new drug application review process through rigorous assessments of product quality attributes. Regulatory reviewers evaluate critical mechanical and sensory parameters, including tablet hardness, friability, palatability profiles, and taste-masking efficiency. Selecting whole-tablet administration for bioequivalence trials minimizes confounding variability arising from individual chewing behaviors and palatability factors, allowing the pharmacokinetic assessment to focus strictly on biopharmaceutic formulation performance.

Disparities across reference listed drug labeling regarding concomitant water consumption also presented regulatory challenges addressed through the harmonized ICH M13A guidance framework. Product labels historically exhibit three divergent patterns: explicit instructions to administer the tablet with water, explicit allowances to take the product with or without water, or complete silence regarding fluid intake. Methylphenidate hydrochloride chewable tablets explicitly direct patients to chew and swallow with water, cetirizine hydrochloride chewable tablets indicate intake with or without water, and loratadine chewable tablets instruct thorough chewing without addressing water consumption. Under the harmonized guidance, when labeling permits administration with or without water, bioequivalence studies must administer test and comparator products without water, which represents the more discriminating evaluation condition.

When product labeling remains entirely silent regarding fluid intake during chewable tablet administration, regulatory determinations rely on historical clinical study protocols from original new drug application approval packages. If original bioavailability or bioequivalence trial protocols documented water administration during reference product approval, subsequent generic bioequivalence studies are instructed to replicate those specific operational conditions. In scenarios where original documentation lacks explicit water specifications, product-specific guidances default to the most discriminating condition, requiring study participants to chew and swallow the tablet without water. This hierarchical evaluation tree ensures reproducible study design standards across generic drug development programs.

The systematic screening methodology employed internal FDA regulatory databases in January 2025, searching labeling text and guidance metadata using the terms chew, chewable, chewed, and chewing. The search retrieved an initial pool of 130 product-specific guidances, comprising 57 hits for chew, 32 for chewable, 34 for chewed, and 7 for chewing. Subsequent filtering excluded seven non-oral dosage forms, eliminated 69 duplicate entries, and restricted the evaluation scope to immediate-release solid oral dosage forms, establishing a final analytical corpus of 35 product-specific guidances. Detailed comparisons against reference listed drug labeling and current guidance principles identified eight specific product-specific guidances requiring formal revision to align with discriminating bioequivalence standards, exemplified by ethinyl estradiol and norethindrone acetate guidances transitioning from chew-and-swallow recommendations to whole-tablet ingestion with water.

Distinct regulatory considerations apply to extended-release formulations that incorporate chewing instructions, representing a unique therapeutic subset not covered under the immediate-release scope of the ICH M13A guidance. Currently approved extended-release products instructing chewing include methylphenidate hydrochloride extended-release chewable tablets and amphetamine mixed salts extended-release tablets, primarily prescribed for pediatric and adolescent populations requiring prolonged therapeutic efficacy during school and work hours.

Water administration protocols for extended-release chewable tablets are determined by the specific conditions used in the original new drug application approval studies. For example, although the labeling for amphetamine mixed salts extended-release tablets does not explicitly specify water intake, the product-specific guidance recommends chewing and swallowing with water. This recommendation aligns with the bioavailability and bioequivalence study protocols that supported the original approval, ensuring that potential generic applicants match the test conditions used to approve the reference product. This consistency is crucial for maintaining regulatory alignment and ensuring that bioequivalence assessments reflect the actual clinical use and approval history of the reference listed drug.

The standardization of these administration methods contributes to broader efforts to globally harmonize bioequivalence study design, reducing duplication of efforts and enabling a single set of studies to meet the standards of multiple regulatory agencies. By clarifying the most discriminating test conditions for both immediate-release and extended-release chewable tablets, the revised product-specific guidances enhance regulatory clarity for industry and support efficient generic drug development. This work underscores the importance of aligning product-specific guidance with current FDA recommendations and international harmonization principles, ultimately supporting patient access to safe and effective generic chewable tablet formulations while ensuring rigorous scientific assessment of therapeutic equivalence.

Subject of Research: Standardization of bioequivalence administration protocols in FDA product-specific guidance for chewable tablets

Article Title: Standardizing bioequivalence administration methods for chewable tablets: aligning product-specific guidance with current FDA recommendations

Article References: Lim, H. L., Boyce, H., Zhang, Q., Kim, M.-J., & Sun, W.-J. (2026). Standardizing bioequivalence administration methods for chewable tablets: aligning product-specific guidance with current FDA recommendations. AAPS Open, 12(1), Article 21. https://doi.org/10.1186/s41120-026-00158-2

Image Credits: AI Generated

DOI: 10.1186/s41120-026-00158-2

Keywords: Bioequivalence, Chewable Tablets, Product-Specific Guidance, FDA BE Guidance, ICH M13A, Abbreviated New Drug Application, Reference Listed Drug, Immediate-Release Dosage Forms, Extended-Release Tablets, Oral Drug Administration, Dissolution Testing, Pharmacokinetic Endpoints, Biopharmaceutics, Lamotrigine, Methylphenidate, Amphetamine, Generic Drug Regulation